These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19491050)

  • 21. Biotech holds its own in Q2.
    Lawrence S
    Nat Biotechnol; 2004 Aug; 22(8):938. PubMed ID: 15286634
    [No Abstract]   [Full Text] [Related]  

  • 22. Is your biotech giving away the store?
    Jacobs T
    Nat Biotechnol; 2002 Nov; 20(11):1079. PubMed ID: 12410245
    [No Abstract]   [Full Text] [Related]  

  • 23. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 24. Biotech financing retrenches in Q2.
    Lawrence S
    Nat Biotechnol; 2006 Aug; 24(8):883. PubMed ID: 16900116
    [No Abstract]   [Full Text] [Related]  

  • 25. Japanese giants renew interest in industrial biotech.
    Sipp D
    Nat Biotechnol; 2005 Mar; 23(3):275-6. PubMed ID: 15765071
    [No Abstract]   [Full Text] [Related]  

  • 26. Biotech marks time in Q3.
    Lawrence S
    Nat Biotechnol; 2005 Nov; 23(11):1332. PubMed ID: 16273049
    [No Abstract]   [Full Text] [Related]  

  • 27. Public biotechnology 2002--the numbers.
    Lähteenmäki R; DeFrancesco L
    Nat Biotechnol; 2003 Jun; 21(6):607-12. PubMed ID: 12776143
    [No Abstract]   [Full Text] [Related]  

  • 28. Let the chips fall where they may.
    Jacobs T
    Nat Biotechnol; 2003 Feb; 21(2):129. PubMed ID: 12560829
    [No Abstract]   [Full Text] [Related]  

  • 29. Valuation--what you need to know.
    Frei P; Leleux B
    Nat Biotechnol; 2004 Aug; 22(8):1049-51. PubMed ID: 15309760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 31. Strategic rethink for German biotechnology.
    Fernandes M; Miska D
    Nat Biotechnol; 2002 Oct; 20(10):970-1. PubMed ID: 12355106
    [No Abstract]   [Full Text] [Related]  

  • 32. A lifeline for the biotech sector.
    Kessel M
    Nat Biotechnol; 2009 Feb; 27(2):123-4. PubMed ID: 19204686
    [No Abstract]   [Full Text] [Related]  

  • 33. Small company mergers--good for whom?
    Maybeck V; Bains W
    Nat Biotechnol; 2006 Nov; 24(11):1343-8. PubMed ID: 17093475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Building a better biotech company.
    Turner L
    Nat Biotechnol; 1999 Feb; 17 Suppl():BE5-6. PubMed ID: 10052312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biotech weathers 2Q12 slump.
    Yang W
    Nat Biotechnol; 2012 Aug; 30(8):738. PubMed ID: 22871704
    [No Abstract]   [Full Text] [Related]  

  • 36. Gold in the ivory tower: equity rewards of outlicensing.
    Edwards M; Murray F; Yu R
    Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixed results in Q1.
    Lawrence S
    Nat Biotechnol; 2005 May; 23(5):518. PubMed ID: 15877059
    [No Abstract]   [Full Text] [Related]  

  • 38. The responsibilities of growing up.
    Nat Biotechnol; 2006 Mar; 24(3):225. PubMed ID: 16525362
    [No Abstract]   [Full Text] [Related]  

  • 39. Korean biotechs seize opportunity to list on public markets.
    Louët S
    Nat Biotechnol; 2005 Oct; 23(10):1189-90. PubMed ID: 16211042
    [No Abstract]   [Full Text] [Related]  

  • 40. Editorial: Biotech in the financial crisis.
    Jungbauer A
    Biotechnol J; 2009 Aug; 4(8):1095. PubMed ID: 19685457
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.